Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]

Intravesical IO using durvalumab shows promising results for patients with high...

Dr Charalampos Fragkoulis - General Hospital of Athens, Athens, Greece

Intravesical IO using durvalumab shows promising results for patients with high risk NMIBC after BCG failure ( Dr Charalampos Fragkoulis - General Hospital of Athens, Athens, Greece )

Choosing cancer medicines wisely in Africa

Dr Harrison Chuwa - The Aga Khan Hospital, Dar Es Salaam, Tanzania

Choosing cancer medicines wisely in Africa ( Dr Harrison Chuwa - The Aga Khan Hospital, Dar Es Salaam, Tanzania )

Navigating evidence-based care with limited resources in Africa

Dr Verna Vanderpuye - National center for Radiotherapy and Nuclear Medicine...

Navigating evidence-based care with limited resources in Africa ( Dr Verna Vanderpuye - National center for Radiotherapy and Nuclear Medicine, Accra, Ghana )

Pembrolizumab plus docetaxel used to treat patients with metastatic castration...

Prof Daniel Petrylak - Yale University Cancer Center, New Haven, USA

Pembrolizumab plus docetaxel used to treat patients with metastatic castration-resistant prostate cancer ( Prof Daniel Petrylak - Yale University Cancer Center, New Haven, USA )

Improving access to palliative care by enhancing primary care services in an...

Dr Malar Velli Segarmurthy - Ministry of Health Malaysia, Putrajaya, Malaysia

Improving access to palliative care by enhancing primary care services in an upper middle-income country ( Dr Malar Velli Segarmurthy - Ministry of Health Malaysia, Putrajaya, Malaysia )

Pembrolizumab shows notable antitumour activity for patients with high-risk...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembrolizumab shows notable antitumour activity for patients with high-risk non–muscle-invasive bladder cancer ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib...

Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC ( Dr Mauricio Burotto - Bradford Hill, Recoleta, Chile )

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low...

Prof Robert A Huddart - Royal Marsden NHS Foundation Trust, London, UK

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low toxicity and good outcomes ( Prof Robert A Huddart - Royal Marsden NHS Foundation Trust, London, UK )

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer